Table 1 Effect of tumor necrosis factor (TNF)-α treatment on ceramide and sphingomyelin content of L6 myotubes.1
From: TNF-α- and tumor-induced skeletal muscle atrophy involves sphingolipid metabolism
Principal molecular species | Ceramide | Sphingomyelin | ||||
|---|---|---|---|---|---|---|
Control, pmol/μg protein | TNF-α, pmol/μg protein | TNF-α-induced increase, % of total control2 | Control, pmol/μg protein | TNF-α, pmol/μg protein | TNF-α-induced decrease, % of total control2 | |
C16:0 | 4.87 ± 0.82 | 6.21 ± 1.06 | 11.5 ± 5.1 | 69.7 ± 10.54 | 47.2 ± 7.66 | 20.4 ± 2.1 |
C18:0 | 1.76 ± 1.11 | 2.48 ± 0.74 | 6.2 ± 2.8 | 6.28 ± 0.94 | 5.35 ± 0.82 | 1.1 ± 0.1 |
C20:0 | 0.07 ± 0.07 | 0.38 ± 0.09 | 1.8 ± 0.3 | 1.29 ± 0.13 | 1.12 ± 0.11 | 0.16 ± 0.07 |
C22:1 | 0.51 ± 0.15 | 0.72 ± 0.14 | 1.5 ± 0.6 | 3.17 ± 0.32 | 2.77 ± 0.38 | 0.54 ± 0.07 |
C22:0 | 0.65 ± 0.18 | 1.05 ± 0.19 | 2.3 ± 0.8 | 3.15 ± 0.6 | 2.62 ± 0.46 | 0.55 ± 0.14 |
C24:1 | 4.77 ± 0.91 | 6.32 ± 1.16 | 9.2 ± 2.3 | 13.7 ± 2.44 | 10.00 ± 1.81 | 2.72 ± 0.22 |
C24:0 | 1.35 ± 0.33 | 1.44 ± 0.21 | 1.5 ± 0.7 | 5.01 ± 1.03 | 4.39 ± 0.94 | 0.55 ± 0.08 |
Total | 14.70 ± 3.40 | 19.70 ± 3.85 | 35.5 ± 8.8 | 118.8 ± 17.2 | 85.7 ± 13.1 | 30.4 ± 2.1 |